Virtual Library
Start Your Search
I. Tominc
Author of
-
+
P2.07 - Poster Session with Presenters Present (ID 468)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Nurses
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.07-006 - Combined Application of Two Biological Medicines with Healthcare and Health Education in Systemic Therapy Clinic (ID 5050)
14:30 - 14:30 | Author(s): I. Tominc
- Abstract
Background:
The incidence of cancer increases along with the number of medicines used for the systemic healing of cancer. By using those medicines some side effects can occur. Trastuzumab could cause cardiovascular problems. The most common side effects of erlotinib are skin rash and diarrhea. The purpose of the study was to assess the difficulties and side effects for the patient receiving a combination of trastuzumab and erlotinib and the health educational role of a nurse in given situation.
Methods:
The case study included a female patient, diagnosed with cancer of the genitals, metastatic lung cancer and breast cancer, treated in the Unit for Medical Oncology clinic, Department of Oncology, University Clinical Centre Maribor. The patient was invited to an interview where the purpose of a case study was explained. The patient could easily refuse to participate in a case study. Data was collected retrograde from medical records and healthcare documentation and from the conversation with the patient for the time period of 18 years, from 1998 to June 2016.
Results:
The patient is receiving the medicine erlotinib in tablet form from 2012 and trastuzumab in the form of subcutaneous injections from 2015. Introducing erlotinib caused no side effects. In November 2014 extended lashes, I. stage skin rash, mild diarrhea and mild conjunctivitis have emerged. All symptoms were controlled by symptomatic therapy. Skin rash of II. - III. stage appeared in January 2015, mostly on the scalp, but the patient nevertheless continued taking biological medicine. In February 2016 the skin rash was reduced after the intensity of the therapy was modulated. After receiving trastuzumab the patient only noticed mild pain in bones and muscles.
Conclusion:
The patient is being monitored since her first diagnosis, through surgical procedures, radiations, chemotherapy and biological medicines treatments. Through conversation we found out that she is conscious, eager for all the available information and that she accepted cancer diagnosis and all the treatment as something she must overcome and talk about. The patient believes that biological medicine application, continuous medical education and healthcare help by overcoming the symptoms of the disease and its side effects. She lives normally, is capable of the efforts of everyday life and during the entire treatment works as a manager. She does not mind coming regularly to the medical oncology clinic.
